BACKGROUND: Next-generation metagenomic sequencing (NGMS) has opened new frontiers in microbial discovery but has been clinically characterized in only a few settings. OBJECTIVE: To explore the plasma virome of persons who inject drugs and to characterize the sensitivity and accuracy of NGMS compared with quantitative clinical standards. DESIGN: Longitudinal and cross-sectional studies. SETTING: A clinical trial (ClinicalTrials.gov: NCT01285050) and a well-characterized cohort study of persons who have injected drugs. PARTICIPANTS: Persons co-infected with hepatitis C virus (HCV) and HIV. MEASUREMENTS: Viral nucleic acid in plasma by NGMS and quantitative polymerase chain reaction (PCR). RESULTS: Next-generation metagenomic sequencing generated a total of 600 million reads, which included the expected HIV and HCV RNA sequences. HIV and HCV reads were consistently identified only when samples contained more than 10 000 copies/mL or IU/mL, respectively, as determined by quantitative PCR. A novel RNA virus, human hepegivirus-1 (HHpgV-1), was also detected by NGMS in 4 samples from 2 persons in the clinical trial. Through use of a quantitative PCR assay for HHpgV-1, infection was also detected in 17 (10.9%) of 156 members of a cohort of persons who injected drugs. In these persons, HHpgV-1 viremia persisted for a median of at least 4538 days and was associated with detection of other bloodborne viruses, such as HCV RNA and SEN virus D. LIMITATION: The medical importance of HHpgV-1 infection is unknown. CONCLUSION: Although NGMS is insensitive for detection of viruses with relatively low plasma nucleic acid concentrations, it may have broad potential for discovery of new viral infections of possible medical importance, such as HHpgV-1. PRIMARY FUNDING SOURCE: National Institutes of Health.
BACKGROUND: Next-generation metagenomic sequencing (NGMS) has opened new frontiers in microbial discovery but has been clinically characterized in only a few settings. OBJECTIVE: To explore the plasma virome of persons who inject drugs and to characterize the sensitivity and accuracy of NGMS compared with quantitative clinical standards. DESIGN: Longitudinal and cross-sectional studies. SETTING: A clinical trial (ClinicalTrials.gov: NCT01285050) and a well-characterized cohort study of persons who have injected drugs. PARTICIPANTS: Persons co-infected with hepatitis C virus (HCV) and HIV. MEASUREMENTS: Viral nucleic acid in plasma by NGMS and quantitative polymerase chain reaction (PCR). RESULTS: Next-generation metagenomic sequencing generated a total of 600 million reads, which included the expected HIV and HCV RNA sequences. HIV and HCV reads were consistently identified only when samples contained more than 10 000 copies/mL or IU/mL, respectively, as determined by quantitative PCR. A novel RNA virus, human hepegivirus-1 (HHpgV-1), was also detected by NGMS in 4 samples from 2 persons in the clinical trial. Through use of a quantitative PCR assay for HHpgV-1, infection was also detected in 17 (10.9%) of 156 members of a cohort of persons who injected drugs. In these persons, HHpgV-1 viremia persisted for a median of at least 4538 days and was associated with detection of other bloodborne viruses, such as HCV RNA and SEN virus D. LIMITATION: The medical importance of HHpgV-1 infection is unknown. CONCLUSION: Although NGMS is insensitive for detection of viruses with relatively low plasma nucleic acid concentrations, it may have broad potential for discovery of new viral infections of possible medical importance, such as HHpgV-1. PRIMARY FUNDING SOURCE: National Institutes of Health.
Authors: Michael G Berg; Deanna Lee; Kelly Coller; Matthew Frankel; Andrew Aronsohn; Kevin Cheng; Kenn Forberg; Marilee Marcinkus; Samia N Naccache; George Dawson; Catherine Brennan; Donald M Jensen; John Hackett; Charles Y Chiu Journal: PLoS Pathog Date: 2015-12-11 Impact factor: 6.823
Authors: Emma Thomson; Camilla L C Ip; Anjna Badhan; Mette T Christiansen; Walt Adamson; M Azim Ansari; David Bibby; Judith Breuer; Anthony Brown; Rory Bowden; Josie Bryant; David Bonsall; Ana Da Silva Filipe; Chris Hinds; Emma Hudson; Paul Klenerman; Kieren Lythgow; Jean L Mbisa; John McLauchlan; Richard Myers; Paolo Piazza; Sunando Roy; Amy Trebes; Vattipally B Sreenu; Jeroen Witteveldt; Eleanor Barnes; Peter Simmonds Journal: J Clin Microbiol Date: 2016-07-06 Impact factor: 11.677
Authors: Patricia J Simner; Heather B Miller; Florian P Breitwieser; Gabriel Pinilla Monsalve; Carlos A Pardo; Steven L Salzberg; Cynthia L Sears; David L Thomas; Charles G Eberhart; Karen C Carroll Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Joel J Credle; Matthew L Robinson; Jonathan Gunn; Daniel Monaco; Brandon Sie; Alexandra Tchir; Justin Hardick; Xuwen Zheng; Kathryn Shaw-Saliba; Richard E Rothman; Susan H Eshleman; Andrew Pekosz; Kasper Hansen; Heba Mostafa; Martin Steinegger; H Benjamin Larman Journal: bioRxiv Date: 2020-06-03
Authors: Nguyen To Anh; Nguyen Thi Thu Hong; Le Nguyen Truc Nhu; Tran Tan Thanh; Catherine Anscombe; Le Ngoc Chau; Tran Thi Thanh Thanh; Chuen-Yen Lau; Direk Limmathurotsakul; Nguyen Van Vinh Chau; H Rogier van Doorn; Xutao Deng; Motiur Rahman; Eric Delwart; Thuy Le; Guy Thwaites; Le Van Tan Journal: Emerg Infect Dis Date: 2018-11 Impact factor: 6.883
Authors: Siddharth Sridhar; Cyril C Y Yip; Nicholas F S Chew; Shusheng Wu; Kit-Hang Leung; Jasper F W Chan; Vincent C C Cheng; Kwok-Yung Yuen Journal: Open Forum Infect Dis Date: 2019-07-12 Impact factor: 3.835